Siemens Sonocur Swings Approval: Low Energy Level Touted For Tennis Elbow
This article was originally published in The Gray Sheet
Executive Summary
Siemens is highlighting a statistically significant pain reduction rate (50%) in nearly two-thirds (64%) of patients using the Sonocur Basic low-energy extracorporeal shockwave therapy system for lateral epicondylitis, or "tennis elbow.
You may also be interested in...
HealthTronics OssaTron Market Expands 10-Fold With Tennis Elbow Indication
FDA approval of HealthTronics' OssaTron high-energy shockwave device for "tennis-elbow" treatment gives the company access to the U.S. general orthopedics market, which includes about 20,000 practices, according to the firm
Xbrane Assembles The Troops As FDA Says No To Lucentis Biosimilar
Xbrane Biopharma was riding the crest of a wave with the EU launch of its biosimilar to Lucentis, following years of toil and investment. However, plans to roll out the product in the US will have to be pushed back – likely – into the middle of 2025, following a US FDA complete response letter.